ir.horizon-pharma.comInvestors | Horizon Therapeutics plc

Skip to main navigation menu Our Company About Us Leadership Team Business Development Grant Programs Medical Education External Research Worldwide Locations Contact Us Our Pipeline Pipeline Teprotumumab Our Medicines Our Portfolio Orphan Rheumatology Inflammation Medicine Support Our Patients Our Commitment Advocacy Overview Resources Disease Information Patient Stories Patient Support Expanded Access Our Culture Who We Are Social Responsibility Our Careers Why Horizon Working At Horizon Search Jobs Investors At a Glance Press Releases Events & Presentations Corporate Governance Governance Overview Whistleblower Hotline Leadership Committee Composition Contact Board Financials & Filings Financial Information SEC Filings GAAP to Non-GAAP Reconciliations Stock Information Stock Quote & Chart Historic Stock Lookup Investment Calculator Analyst Coverage Annual Reports / Proxy Statements Investors FAQs IR Contact Us IR Email Alerts United States Canada Investors Media Center Follow Us Search United States Canada Search Investors Investors Corporate Profile Horizon is a biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. Horizon's global headquarters is in Dublin, Ireland. The Company also has offices in Lake Forest, Ill.; Chicago, Ill.; Brisbane, Calif.; Novato, Calif.; Washington, D.C. and Mannheim, Germany. Upcoming Events There are currently no events to display. Stock Quote Volume: Data as of 05/16/20 9:18 am EDT Copyright West LLC. Minimum 15 minutes delayed. Refresh Quote Press Releases Date Title 05/14/20 Summary Toggle New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy 05/11/20 Summary Toggle U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life 05/06/20 Summary Toggle Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance Investor Presentation 2019 Annual Report Curzion Acquisition Investor Relations Investors Press Releases Events & Presentations Corporate Governance Governance Overview Whistleblower Hotline Leadership Team Committee Composition Contact the Board Financial & Filings Financial Information SEC Filings Stock Information Stock Quote & Chart Historic Stock Lookup Investment Calculator Analyst Coverage Annual Reports / Proxy Statements Investor FAQs Contact Us Email Alerts Investor Contacts Tina Ventura Senior Vice President, Investor Relations Investor-relations@horizontherapeutics.com Ruth Venning Executive Director, Investor Relations Investor-relations@horizontherapeutics.com U.S. Media Contact Geoff Curtis Executive Vice President, Corporate Affairs & Chief Communications Officer media@horizontherapeutics.com +1 888 506-2562 Ireland Media Contact Ray Gordon Gordon MRM ray@gordonmrm.ie +353 (87) 2417373 Shareholder Tools Shareholder Tools Email Alerts Subscription RSS News Feeds Snapshot Print Our Company Our Pipeline Our Medicines Our Patients Our Culture Our Careers Investors Follow Us © 2020 Horizon Therapeutics plc Global Privacy Policy Legal Notice Contact Us The information provided in this site is intended only for residents of the U.S. You are leaving horizontherapeutics.com You are leaving horizontherapeutics.com. You will be redirected to a website operated by an independent third party. This link is provided solely for your convenience. Continue Cancel...